Magazine Article | March 1, 2022

Why Biotechs Need A Practical Approach To Going Public

Source: Life Science Leader

By David Diamond

With the interest surrounding investment in the biotech field, many biotech companies are entering the public market significantly earlier than before. This is as true for companies funded by friends and family as it is for those that have venture capital backing.

If a biotech is looking to trade on major exchanges such as Nasdaq or the New York Stock Exchange (NYSE), it is important to understand that there are a variety of challenges that emerge based on the avenues taken to ensure the funding necessary to then enter the public markets. Biotechs, in particular, may want to be mindful of the ramifications of the avenue they choose.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: